Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
about
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsThe combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancerCirculating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC.The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.Circulating DNA in EGFR-mutated lung cancer.Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study.Possible application of circulating free tumor DNA in non-small cell lung cancer patients.Targeting protein for Xenopus kinesin-like protein 2 knockdown enhances radiation sensitivity of human lung squamous carcinoma cell.Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer.PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer.The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.Personalized therapy for lung cancer: Striking a moving target
P2860
Q28077570-CACB1010-71CE-4227-9AEC-2FE5A8D92F94Q33591586-A63FDB73-3746-451C-AC32-96820461AFD7Q33640472-09BA6E82-6764-47C7-9E68-4E4C777AC165Q37690677-7265B543-F799-42A0-9274-7735B198DA63Q40206402-45F7005F-1075-4BF2-BD79-4AB9D8AE3B5DQ40489387-A89B0B44-8A56-4F55-ADB3-73B6C9A704E9Q41347759-049EBEA1-D198-4974-BE1C-DB48B1040507Q42283950-9485EBA6-8C82-4C1D-A31C-9E4677CF6574Q46917029-B51EA98E-69FC-4C4C-8DE4-5313A9622757Q47155456-1136A155-6000-4F69-95FC-32A1FC24A84AQ47158413-6E410AA3-1905-436B-B8B2-6D4733166E28Q48242860-5BD14D2A-05C4-41C1-B91F-21BD0315B225Q49217100-65F58BFA-AE04-45E4-B48A-E6E4D4D188A2Q49667322-0CAEEB87-B8F7-41C9-8B18-9A54BB1120FCQ49740946-B8A26E2E-1135-433D-A9B6-52D9E612FDB2Q50646630-DCA7379B-F460-42F8-8BB2-841E7A569C4FQ52622918-4C60A783-FFE6-4C19-8D54-465B159925F7Q58792324-5E2391AF-5093-48F9-A258-F69866966021
P2860
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@en
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@nl
type
label
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@en
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@nl
prefLabel
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@en
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
Circulating cell-free DNA as a ...... in non-small cell lung cancer.
@en
P2093
P2860
P304
44583-44595
P356
10.18632/ONCOTARGET.10069
P407
P577
2016-06-15T00:00:00Z